| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 1 | +100.00% | -6.15% | +3.27% | -9.42% | -9.42% | — |
| 14d | 1 | +100.00% | -7.02% | +0.91% | -7.93% | -7.93% | — |
| 30d | 1 | +100.00% | -7.83% | -3.30% | -4.53% | -4.53% | — |
| 60d | 1 | +100.00% | -0.30% | +1.55% | -1.85% | -1.85% | — |
| 90d | 1 | +100.00% | -7.07% | +5.82% | -12.89% | -12.89% | — |
| 180d | 1 | +0.00% | +2.98% | +16.54% | -13.56% | -13.56% | — |
| 1y | 1 | +100.00% | -23.87% | +32.55% | -56.41% | -56.41% | — |
| 2y | 1 | +100.00% | -50.85% | +25.34% | -76.19% | -76.19% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED |
|---|---|---|---|---|---|---|---|
| TBPH THERAVANCE BIOPHARMA, INC. | SALE Chief Medical Officer | 35,672 | $18.79 | $670.3K | 242,499 | Feb 20, 2021 | Feb 23, 2021 ↗ |
| TBPH THERAVANCE BIOPHARMA, INC. | SALE Chief Medical Officer | 4,639 | $17.21 | $79.8K | 278,171 | Nov 20, 2020 | Nov 24, 2020 ↗ |
| TBPH THERAVANCE BIOPHARMA, INC. | SALE Chief Medical Officer | 25,000 | $18.29 | $457.2K | 282,810 | Aug 21, 2020 | Aug 24, 2020 ↗ |
| TBPH THERAVANCE BIOPHARMA, INC. | SALE Chief Medical Officer | 4,646 | $18.22 | $84.7K | 307,810 | Aug 20, 2020 | Aug 24, 2020 ↗ |
| TBPH THERAVANCE BIOPHARMA, INC. | SALE SVP Clin Dev & Chief Med Ofc | 4,212 | $26.67 | $112.3K | 312,456 | May 20, 2020 | May 22, 2020 ↗ |
| TBPH THERAVANCE BIOPHARMA, INC. | SALE SVP Clin Dev & Chief Med Ofc | 33,608 | $25.90 | $870.4K | 316,668 | Feb 20, 2020 | Feb 24, 2020 ↗ |
| TBPH THERAVANCE BIOPHARMA, INC. | PURCHASEGRANT Stock grant | 54,000 | — | — | 350,276 | Feb 3, 2020 | Feb 5, 2020 ↗ |
| TBPH THERAVANCE BIOPHARMA, INC. | PURCHASEGRANT Stock grant | 65,000 | — | — | 296,276 | Feb 3, 2020 | Feb 5, 2020 ↗ |